Horizon Pharma Inc. (HZNP) Rating Reiterated by BMO Capital Markets
Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “outperform” rating reiterated by equities researchers at BMO Capital Markets in a report released on Monday. They presently have a $29.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would indicate a potential upside of 37.77% from the stock’s current price.
HZNP has been the subject of a number of other reports. Morgan Stanley set a $24.00 price objective on Horizon Pharma and gave the company a “hold” rating in a report on Monday, September 12th. Mizuho restated a “buy” rating on shares of Horizon Pharma in a report on Thursday, September 29th. Piper Jaffray Cos. restated an “overweight” rating and issued a $33.00 price objective (down from $34.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Citigroup Inc. increased their price objective on Horizon Pharma from $18.00 to $21.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and issued a $27.00 price objective on shares of Horizon Pharma in a report on Thursday, September 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $29.62.
Shares of Horizon Pharma (NASDAQ:HZNP) opened at 21.05 on Monday. Horizon Pharma has a one year low of $13.05 and a one year high of $23.44. The company’s market capitalization is $3.39 billion. The stock has a 50 day moving average price of $18.75 and a 200-day moving average price of $18.60.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.07. The business earned $273.70 million during the quarter, compared to the consensus estimate of $270.04 million. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. Horizon Pharma’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. On average, equities research analysts expect that Horizon Pharma will post $2.02 EPS for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new position in shares of Horizon Pharma during the third quarter valued at $112,000. Societe Generale acquired a new position in shares of Horizon Pharma during the second quarter valued at $117,000. SG Americas Securities LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $117,000. Nuveen Asset Management LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $176,000. Finally, Profund Advisors LLC acquired a new position in shares of Horizon Pharma during the second quarter valued at $194,000. 86.91% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.